Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder
Let's break down the science, practical applications, and how lifters and dieters alike might benefit from this unique compound
The obesity and type 2 diabetes mellitus epidemics have prompted expanded use of incretin-based therapies
Still, many patients face steep costs and limited insurance coverage
It really works against all major substances, and it works uniformly, not because it acts against alcohol or opioids or nicotine specifically, but because it is likely acting against the craving itself